Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 677-681

  Jenkins, Christopher ^a   Hewamana, Saman ^a,b   Krige, David ^c   Pepper, Chris ^a   Burnett, Alan ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Chroma Therapeutics Ltd   (United Kingdom)

Author keywords

Acute myeloid leukemia; Aminopeptidases; CD13; CHR 2797; Metalloenzymes; Molecular therapeutics; Tosedostat

Indexed keywords

AMINOPEPTIDASE; CHR 79888; CYTARABINE; PEPTIDE HYDROLASE INHIBITOR; TOSEDOSTAT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; AMINOPEPTIDASES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CULTURE TECHNIQUES; CYTARABINE; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FEMALE; GLYCINE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 79954577236     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.030     Document Type: Article

References (10)

1. Ashmun R.A., Look A.T. Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood 1990, 75:462-469.
2. Kenny A.J., O'Hare M.J., Gusterson B.A. Cell-surface peptidases as modulators of growth and differentiation. Lancet 1989, 2:785-787.
3. Wilson J.G. Adhesive interactions in hemopoiesis. Acta Haematol 1997, 97:6-12.
4. Krige D., Needham L.A., Bawden L.J., Flores N., Farmer H., Miles L.E., et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 2008, 68:6669-6679.
5. Moore H., Davenport E., Smith E., Muralikrishnan S., Dunlop A.S., Walker B.A., et al. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 2009, 8(4):762-770.
6. Chou T.C., Talalay P. Quantitative-analysis of dose-effect relationships - the combined effects of multiple-drugs or enzyme-inhibitors. Adv Enzyme Regul 1984, 22:27-55.
7. Aozuka Y., Koizumi K., Saitoh Y., Ueda Y., Sakarai H., Saiki I., et al. Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implemented into syngeneic mice. Cancer Lett 2004, 216:35-42.
8. Plesa C., Chelghoum Y., Plesa A., Elhamri M., Tigaud I., Michallet M., et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer 2008, 112(3):572-580.
9. Lowenberg B., Davies F., Müller-Tidow C., Dührsen U., Burnett A., Zachée P., et al. A multicentre Phase II study of the aminopeptidase inhibitor, CHR-2797, in the treatment of elderly and/or previously treated patients with acute myeloid leukemia. Blood 2008, 112. (Abstract 961).
10. Cortes J., Feldman E., Yee K., Toal M., Richardson A., Charman A., Flores N. The OPAL study: a phase II study to evaluate the efficacy, safety, and tolerability of tosedostat (CHR-2797) in elderly subjects with treatment refractory or relapsed acute myeloid leukemia. J Clin Oncol 2010, 28(15s). (abstract TPS277).